📣 VC round data is live. Check it out!
- Public Comps
- Idorsia
Idorsia Valuation Multiples
Discover Idorsia's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Inhibrx Biosciences, Precigen, Immatics, Semnur Pharmaceuticals and more.
Idorsia Overview
About Idorsia
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. It is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. Idorsia's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
Founded
2017
HQ

Employees
552
Website
Financials (LTM)
EV
$3B
Valuation Multiples
Start free trialIdorsia Financials
Idorsia reported last 12-month revenue of $284M and negative EBITDA of ($82M).
In the same LTM period, Idorsia generated $254M in gross profit, ($82M) in EBITDA losses, and had net loss of ($148M).
Revenue (LTM)
Idorsia P&L
In the most recent fiscal year, Idorsia reported revenue of $281M and EBITDA of ($58M).
Idorsia is unprofitable as of last fiscal year, with gross margin of 91%, EBITDA margin of (21%), and net margin of (45%).
Financial data powered by Morningstar, Inc.
Idorsia Stock Performance
Idorsia has current market cap of $1B, and enterprise value of $3B.
Market Cap Evolution
Idorsia's stock price is $5.39.
Idorsia share price decreased by 5.8% in the last 30 days, and increased by 96.7% in the last year.
Idorsia has an EPS (earnings per share) of $-0.49.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $1B | -4.0% | -5.8% | 21.3% | 96.7% | $-0.49 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialIdorsia Valuation Multiples
Idorsia trades at 10.3x EV/Revenue multiple, and (35.9x) EV/EBITDA.
EV / Revenue (LTM)
Idorsia Financial Valuation Multiples
As of June 4, 2026, Idorsia has market cap of $1B and EV of $3B.
Idorsia has a P/E ratio of (9.3x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Idorsia Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Idorsia Margins & Growth Rates
Idorsia grew revenue by 3% but EBITDA decreased by 4% in the last fiscal year.
In the most recent fiscal year, Idorsia reported gross margin of 91%, EBITDA margin of (21%), and net margin of (45%).
Idorsia Margins
Idorsia Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Idorsia Operational KPIs
Idorsia's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.7M for the same period.
Idorsia's Rule of 40 is (16%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Idorsia's Rule of X is (12%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Idorsia Competitors
Idorsia competitors include Inhibrx Biosciences, Precigen, Immatics, Semnur Pharmaceuticals, Sinopep, Ardelyx, Uniphar, Celltrion Pharm, ArriVent BioPharma and Septerna.
Most Idorsia public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1072.6x | 1855.4x | (11.1x) | - | |||
| 146.1x | 24.3x | (12.7x) | (20.8x) | |||
| 15.3x | 17.0x | (4.4x) | (3.7x) | |||
| - | - | - | - | |||
| 5.7x | - | 14.9x | - | |||
| 3.3x | 2.9x | (45.7x) | (107.1x) | |||
| 0.5x | 0.5x | 11.6x | 11.1x | |||
| 3.9x | - | 26.4x | - | |||
This data is available for Pro users. Sign up to see all Idorsia competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Idorsia
Idorsia has acquired 1 company to date.
Last acquisition by Idorsia was on July 23rd 2020. Idorsia acquired Vaxxilon for $2M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Idorsia
| Description | - |
| HQ Country | |
| HQ City | Basel |
| Deal Date | 23 Jul 2020 |
| Valuation | $2M |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Idorsia acquisitions and their M&A valuation multiples. Start Free Trial | |
Investments by Idorsia
Idorsia has invested in 1 company to date.
Latest investment by Idorsia was on October 30th 2016. Idorsia invested in Owkin in their $2M Seed round (EV/Revenue multiple available to Pro users).
Latest Investments by Idorsia
| Description | Owkin is a Paris-headquartered AI company with offices in New York and London, founded in 2016, that accelerates drug discovery and clinical trials using federated learning. It partners with Sanofi and Servier to analyze siloed biomedical data for cancer treatments, identifying drug candidates and diagnostic tools while preserving patient privacy. The company raised over $255 million, achieving unicorn status in 2021 via a $180 million Sanofi investment. |
| HQ Country | |
| HQ City | New York City, NY |
| Deal Date | 30 Oct 2016 |
| Round | Seed |
| Raised | $2M |
| Investors | Brent Hoberman; Idorsia; Jorg Mohaupt; NJF Capital; Shana Fisher |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Idorsia investments and their VC round multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Idorsia
| When was Idorsia founded? | Idorsia was founded in 2017. |
| Where is Idorsia headquartered? | Idorsia is headquartered in Switzerland. |
| How many employees does Idorsia have? | As of today, Idorsia has over 552 employees. |
| Is Idorsia publicly listed? | Yes, Idorsia is a public company listed on SIX Swiss Exchange. |
| What is the stock symbol of Idorsia? | Idorsia trades under IDIA ticker. |
| When did Idorsia go public? | Idorsia went public in 2017. |
| Who are competitors of Idorsia? | Idorsia main competitors include Inhibrx Biosciences, Precigen, Immatics, Semnur Pharmaceuticals, Sinopep, Ardelyx, Uniphar, Celltrion Pharm, ArriVent BioPharma, Septerna. |
| What is the current market cap of Idorsia? | Idorsia's current market cap is $1B. |
| What is the current revenue of Idorsia? | Idorsia's last 12 months revenue is $284M. |
| What is the current revenue growth of Idorsia? | Idorsia revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of Idorsia? | Current revenue multiple of Idorsia is 10.3x. |
| Is Idorsia profitable? | No, Idorsia is not profitable. |
| What is the current EBITDA of Idorsia? | Idorsia has negative EBITDA and is not profitable. |
| What is Idorsia's EBITDA margin? | Idorsia's last 12 months EBITDA margin is (29%). |
| What is the current EV/EBITDA multiple of Idorsia? | Current EBITDA multiple of Idorsia is (35.9x). |
| What is the current FCF of Idorsia? | Idorsia's last 12 months FCF is ($164M). |
| What is Idorsia's FCF margin? | Idorsia's last 12 months FCF margin is (58%). |
| What is the current EV/FCF multiple of Idorsia? | Current FCF multiple of Idorsia is (17.9x). |
| How many companies Idorsia has acquired to date? | As of June 2026, Idorsia has acquired 1 company. |
| What was the largest acquisition by Idorsia? | $2M acquisition of Vaxxilon on 23rd July 2020 was the largest M&A Idorsia has done to date. |
| What companies Idorsia acquired? | Idorsia acquired Vaxxilon. |
| In how many companies Idorsia has invested to date? | As of June 2026, Idorsia has invested in 1 company. |
| What was the last Idorsia investment? | On 30th October 2016 Idorsia invested in Owkin, participating in a $2M Seed round, alongside Brent Hoberman, Jorg Mohaupt, NJF Capital, and Shana Fisher. |
| In what companies Idorsia invested in? | Idorsia invested in Owkin. |
See public comps similar to Idorsia
Lists including Idorsia
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

